Sequella Inc:医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Sequella Inc - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C6486
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sequella Inc (Sequella) is a clinical-stage pharma company that develops antibiotics to address drug resistant bacterial, fungal, and parasitic infections. The company’s pipeline products comprise SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid antibiotic susceptibility test, B-SMART. Sequella develops antibodies for infections such as mycobacterium tuberculosis, helicobacter pylori, clostridium difficile, avium paratuberculosis and nontuberculous mycobacterial infections. The company also develops antibodies for mycobacterium tuberculosis such as multidrug-resistant TB and extremely drug-resistant TB diseases. It develops drugs through strategic partnerships and alliances. Sequella is headquartered in Rockville, Maryland, the US.

Sequella Inc – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sequella Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Sequella Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Sequella Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Sequella Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Sequella Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Sequella Inc, Medical Equipment, Deal Details 10
Venture Financing 10
Sequella Raises USD1.7 Million in Financing Round 10
Sequella Raises US$0.55 Million In Venture Financing 11
Partnerships 12
Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 12
Sequella Inc – Key Competitors 13
Sequella Inc – Key Employees 14
Sequella Inc – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Sequella Inc, Medical Equipment, Key Facts 2
Sequella Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Sequella Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Sequella Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Sequella Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Sequella Inc, Deals By Market, 2012 to YTD 2018 8
Sequella Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Sequella Raises USD1.7 Million in Financing Round 10
Sequella Raises US$0.55 Million In Venture Financing 11
Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 12
Sequella Inc, Key Competitors 13
Sequella Inc, Key Employees 14

List of Figures
Sequella Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Sequella Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Sequella Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Sequella Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Sequella Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Sequella Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Sequella Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Sequella Inc:医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Puget Energy, Inc.:企業の戦略・SWOT・財務分析
    Puget Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Puget Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • El Puerto de Liverpool SAB de CV:企業の戦略・SWOT・財務情報
    El Puerto de Liverpool SAB de CV - Strategy, SWOT and Corporate Finance Report Summary El Puerto de Liverpool SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Probiogen AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Probiogen AG (Probiogen) a subsidiary of Minapharm Pharmaceuticals & Chemical Industries is a contract development and manufacturing organization that offers cell line engineering, process development and GMP manufacturing of biopharmaceuticals. The organization’s services comprise therapeut …
  • Oval Medical Technologies Ltd-医療機器分野:企業M&A・提携分析
    Summary Oval Medical Technologies Ltd (Oval Medical), a subsidiary of SMC Ltd is a medical device company that develops revolutionary autoinjectors. The company designs and develops drug delivery devices and drug delivery solutions. Its technologies are used to deliver viscous formulations and sensi …
  • Unum Group:企業の戦略・SWOT・財務情報
    Unum Group - Strategy, SWOT and Corporate Finance Report Summary Unum Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Tech Mahindra Limited:企業の戦略・SWOT・財務分析
    Tech Mahindra Limited - Strategy, SWOT and Corporate Finance Report Summary Tech Mahindra Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • University of Texas Health Science Center at San Antonio-製薬・医療分野:企業M&A・提携分析
    Summary University of Texas Health Science Center at San Antonio (UTHSCSA), a subsidiary of University of Texas System is an educational university that offers undergraduate, graduate, and research programs to physicians, biomedical scientists, aging and longevity, cancer, cardiovascular, diabetes, …
  • Realty Income Corporation:企業のM&A・事業提携・投資動向
    Realty Income Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Realty Income Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Maxim Integrated Products, Inc.:企業の戦略・SWOT・財務分析
    Maxim Integrated Products, Inc. - Strategy, SWOT and Corporate Finance Report Summary Maxim Integrated Products, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • NORDSEE GmbH.:企業の戦略・SWOT・財務情報
    NORDSEE GmbH. - Strategy, SWOT and Corporate Finance Report Summary NORDSEE GmbH. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Orbotech Ltd. (ORBK):企業の財務・戦略的SWOT分析
    Orbotech Ltd. (ORBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • REV Group, Inc. (REVG):企業の財務・戦略的SWOT分析
    REV Group, Inc. (REVG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Italgas SpA-石油・ガス分野:企業M&A・提携分析
    Summary Italgas SpA (Italgas), a subsidiary of Snam SpA, is an oilfield service company that offers transportation and dispatching of natural gas, liquefied natural gas regasification, and storage and distribution of natural gas. The company's activities include rhino-analytical tests; instrumental …
  • Center for Applied Medical Research-製薬・医療分野:企業M&A・提携分析
    Summary Center for Applied Medical Research (CIMA), a subsidiary of University of Navarra is a medical research center that carries out research in the therapeutic areas of cardiovascular sciences, gene therapy and hepatology, oncology and neurosciences. The center also provides support services suc …
  • Cardiac Science Corp:企業の戦略的SWOT分析
    Cardiac Science Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Papeles y Cartones de Europa SA:企業の戦略・SWOT・財務情報
    Papeles y Cartones de Europa SA - Strategy, SWOT and Corporate Finance Report Summary Papeles y Cartones de Europa SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Laredo Petroleum Inc (LPI):企業の財務・戦略的SWOT分析
    Laredo Petroleum Inc (LPI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Subaru Corporation (7270):企業の財務・戦略的SWOT分析
    Subaru Corporation (7270) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Alps Industries Ltd.:企業の戦略・SWOT・財務情報
    Alps Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Alps Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Zynerba Pharmaceuticals Inc (ZYNE):製薬・医療:M&Aディール及び事業提携情報
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company provides pipeline product candidates such as ZYN002 and ZYN001. Its ZYN002 is a synthetic CBD, a non-psychoactive cannabinoid, formu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆